Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | CES2 | O00748 | 3/20 | 0.45 |
| ▸ | CES1 | P23141 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421224 | 1.00 | TSHR (0.61) | TSHRTHRBCES2CES1EPHX2 | |
| SCHEMBL1610834 | 1.00 | TSHR (0.61) | TSHRTHRBCES2CES1EPHX2 | |
| SCHEMBL130739 | 1.00 | TSHR (0.61) | TSHRTHRBCES2CES1EPHX2 | |
| SCHEMBL17261284 | 1.00 | TSHR (0.61) | TSHRTHRBCES2CES1EPHX2 | |
| SCHEMBL1611495 | 1.00 | TSHR (0.61) | TSHRTHRBCES2CES1EPHX2 | |
| SCHEMBL79575 | 1.00 | TSHR (0.61) | TSHRTHRBCES2CES1EPHX2 | |
| SCHEMBL28406 | 1.00 | — | — | |
| SCHEMBL17261285 | 1.00 | TSHR (0.61) | TSHRTHRBCES2CES1EPHX2 | |
| SCHEMBL1609522 | 1.00 | TSHR (0.61) | TSHRTHRBCES2CES1EPHX2 | |
| SCHEMBL1612066 | 1.00 | TSHR (0.61) | TSHRTHRBCES2CES1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110577557-A | sialic acid lipid derivative and preparation method and application thereof | 沈阳药科大学 | 2019-12-17 | — | — | CN | claimed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-0908473-B1 | Styrene polymers, chemically-amplified positive resist compositions, their preparation and use in a patterning process | SHINETSU CHEMICAL CO (JP) | 2006-02-01 | — | — | EP | claimed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | claimed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | claimed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | claimed |
| US-5853939-A | Toner for electrostatic image development | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-12-29 | — | — | US | claimed |
| US-5034309-A | Used for forming a recording layer | HITACHI CHEMICAL CO., LTD. (JP) | 1991-07-23 | — | — | US | claimed |
| US-20230293629-A1 | METHODS FOR ATTENUATING RELEASE OF INFLAMMATORY MEDIATORS AND PEPTIDES USEFUL THEREIN | BIOMARCK PHARMACEUTICALS LTD (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230104971-A1 | ELECTROSTATIC CHARGE IMAGE DEVELOPING TONER SET, ELECTROSTATIC CHARGE IMAGE DEVELOPER SET, AND TONER CARTRIDGE SET | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2023-04-06 | — | — | US | disclosed |
| CN-115840343-A | Toner set for electrostatic latent image development, electrostatic latent image developer set, toner cartridge set, process cartridge, image forming apparatus, and image forming method | 富士胶片商业创新有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-11591354-B2 | Thiamine compound, preparation method and pharmaceutical composition thereof | SHANGHAI RAISING PHARMACEUTICAL CO., LTD. (CN) | 2023-02-28 | — | — | US | disclosed |
| EP-0357360-A2 | Naphthalocyanine derivatives, production thereof and optical recording medium using the same | Hitachi Chemical Co., Ltd. (JP) | 1990-03-07 | — | — | EP | disclosed |
| US-4891298-A | DIFFUSION TRANSFER; LIGHT-ABSORBING, PH-SENSITIVE OPTICAL FILTER AGENTS, PHTHALIDE OR NAPHTHALIDE | POLAROID CORPORATION (US) | 1990-01-02 | — | — | US | disclosed |
| US-4886733-A | Photographic products and processes | POLAROID CORPORATION (US) | 1989-12-12 | — | — | US | disclosed |
| EP-0296876-A2 | Naphthalocyanine derivatives and their use in optical recording medium | Hitachi Chemical Co., Ltd. (JP) | 1988-12-28 | — | — | EP | disclosed |
| EP-0284370-A2 | Naphthalocyanine derivatives and production processes thereof, as well as optical information recording media using the derivatives and production processes thereof | Hitachi Chemical Co., Ltd. (JP) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591354-B2 | Thiamine compound, preparation method and pharmaceutical composition thereof | SLC19A2, APP, BACE1 | TSHR 553/4885THRB 112/4885CES2 4120/4885 |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | TSHR 3410/4885THRB 3434/4885CES2 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.